Research Report Screener Results

Chart, Financials, Historical Prices, Industry, Insider, Messages, Options, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 24-Nov-2009
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 40)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
24-Nov-09 New Constructs, LLC N/A IMGN: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
23-Nov-09 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
23-Nov-09 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
22-Nov-09 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: IMMUNOGEN INC 5 $25 View Abstract
20-Nov-09 Ford Investor Services, Inc. N/A Value Graph: IMMUNOGEN -- IMGN 1 $4 View Abstract
20-Nov-09 Ford Investor Services, Inc. N/A Industry Value Graph: EXEL , IMGN , MAXY , ONXX , VRNM -- DRUGS 3 $4 View Abstract
17-Nov-09 Wall Street Transcript ,The The Wall St Transcript MANAGEMENT TURNOVER REPORT - ImmunoGen, Inc. (IMGN) 5 $50 View Abstract
16-Nov-09 Zacks Investment Research Inc. N/A IMMUNOGEN INC (IMGN) Zacks Company Snapshot 1 $10 View Abstract
15-Nov-09 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: IMMUNOGEN INC 5 $25 View Abstract
12-Nov-09 Institutional Shareholder Services N/A ISS Report on Immunogen, Inc. 18 $135 View Abstract
Next 20

Brokerage Reports (Showing 1 to 5 of 5)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
30-Oct-09 Brean Murray & Co., Inc. Ling Wang CFA IMGN: Significant Data Presentations Before Year-End; Reiterate Buy 5 $10 View Abstract
30-Oct-09 Brean Murray & Co., Inc. Ryan Worst CFA, Andrey Glukhov CFA, Daniel Fidell, Jose Haresco, Ling Wang CFA, Bret Jones, Ananda Baruah Morning Insight (AMSC, BYI, PFWD, ATHN, PMTI, IMGN, EK, IM, AVT, MCRS) 13 $50 View Abstract
29-Oct-09 Thomson StreetEvents N/A IMGN - Event Transcript of ImmunoGen, Inc. conference call, Oct. 29, 2009 / 4:30pm ET 11 $75 View Abstract
13-Oct-09 Brean Murray & Co., Inc. Ling Wang CFA IMGN: Initiating Coverage with a Buy Rating and $14 Target Price 22 $75 View Abstract
8-Oct-09 Brean Murray & Co., Inc. Ling Wang CFA Morning Insight (CRIS, IMGN, ARIA) 5 $10 View Abstract

Independent Reports (Showing 1 to 10 of 35)

Release
Date Contributor Author Title Pages Price More Info
24-Nov-09 New Constructs, LLC N/A IMGN: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
23-Nov-09 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
23-Nov-09 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
22-Nov-09 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: IMMUNOGEN INC 5 $25 View Abstract
20-Nov-09 Ford Investor Services, Inc. N/A Value Graph: IMMUNOGEN -- IMGN 1 $4 View Abstract
20-Nov-09 Ford Investor Services, Inc. N/A Industry Value Graph: EXEL , IMGN , MAXY , ONXX , VRNM -- DRUGS 3 $4 View Abstract
17-Nov-09 Wall Street Transcript ,The The Wall St Transcript MANAGEMENT TURNOVER REPORT - ImmunoGen, Inc. (IMGN) 5 $50 View Abstract
16-Nov-09 Zacks Investment Research Inc. N/A IMMUNOGEN INC (IMGN) Zacks Company Snapshot 1 $10 View Abstract
15-Nov-09 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: IMMUNOGEN INC 5 $25 View Abstract
12-Nov-09 Institutional Shareholder Services N/A ISS Report on Immunogen, Inc. 18 $135 View Abstract
Next 20

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.